(Q68809345)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:3491089%20AND%20SRC:MED&resulttype=core&format=json

27 September 2019

title

The development of anti-interleukin-2 antibodies in patients treated with recombinant human interleukin-2 (IL-2) (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:3491089%20AND%20SRC:MED&resulttype=core&format=json

27 September 2019

author name string

M Allegretta

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:3491089%20AND%20SRC:MED&resulttype=core&format=json

27 September 2019

M B Atkins

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:3491089%20AND%20SRC:MED&resulttype=core&format=json

27 September 2019

R A Dempsey

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:3491089%20AND%20SRC:MED&resulttype=core&format=json

27 September 2019

E C Bradley

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:3491089%20AND%20SRC:MED&resulttype=core&format=json

27 September 2019

M W Konrad

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:3491089%20AND%20SRC:MED&resulttype=core&format=json

27 September 2019

A Childs

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:3491089%20AND%20SRC:MED&resulttype=core&format=json

27 September 2019

S N Wolfe

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:3491089%20AND%20SRC:MED&resulttype=core&format=json

27 September 2019

J W Mier

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:3491089%20AND%20SRC:MED&resulttype=core&format=json

27 September 2019

publication date

1 November 1986

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:3491089%20AND%20SRC:MED&resulttype=core&format=json

Journal of Clinical Immunology

27 September 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:3491089%20AND%20SRC:MED&resulttype=core&format=json

27 September 2019

volume

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:3491089%20AND%20SRC:MED&resulttype=core&format=json

27 September 2019

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:3491089%20AND%20SRC:MED&resulttype=core&format=json

27 September 2019

page(s)

481-490

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:3491089%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/bf00915254

27 September 2019

exact match

0 references

cites work

In vivo administration of purified human interleukin 2. I. Half-life and immunologic effects of the Jurkat cell line-derived interleukin 2.

1 reference

12 December 2020

T cell growth factor: parameters of production and a quantitative microassay for activity

1 reference

12 December 2020

Cloned cell lines with natural killer activity. Specificity, function, and cell surface markers

1 reference

12 December 2020

Recombinant Leukocyte A Interferon: Pharmacokinetics, Single-Dose Tolerance, and Biologic Effects in Cancer Patients

1 reference

12 December 2020

Interferon-neutralizing antibodies in a patient treated with human fibroblast interferon

1 reference

12 December 2020

Site-specific mutagenesis of the human interleukin-2 gene: structure-function analysis of the cysteine residues

1 reference

12 December 2020

Interleukin-2 augments natural killer cell activity

1 reference

12 December 2020

Biological Activity of Recombinant Human Interleukin-2 Produced inEscherichia coli

1 reference

12 December 2020

Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2.

1 reference

12 December 2020

Structure and expression of a cloned cDNA for human interleukin-2.

1 reference

12 December 2020

Lymphokine-activated killer cell phenomenon. II. Precursor phenotype is serologically distinct from peripheral T lymphocytes, memory cytotoxic thymus-derived lymphocytes, and natural killer cells

1 reference

12 December 2020

The suppressive effect of a supernate from concanavalin A-activated human lymphocytes: Effects of concanavalin A-activated lymphocytes and their supernates on cytotoxic and mixed lymphocyte reactions

1 reference

12 December 2020

The differential effects of human leukocyte pyrogen/lymphocyte-activating factor, T cell growth factor, and interferon on human natural killer activity

1 reference

12 December 2020

Soluble inhibitory factor (SIF) in normal human serum

1 reference

12 December 2020

In vivo administration of purified human interleukin 2. II. Half life, immunologic effects, and expansion of peripheral lymphoid cells in vivo with recombinant IL 2.

1 reference

12 December 2020

Functional and morphologic characterization of human T cells continuously grown in vitro

1 reference

12 December 2020

Antibodies to alpha-interferon in a patient with systemic lupus erythematosus

1 reference

12 December 2020

Identification of tissue-specific nuclear antigens transferred to nitrocellulose from polyacrylamide gels.

1 reference

12 December 2020

Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes

1 reference

12 December 2020

Lymphokine-activated killer cell phenomenon. III. Evidence that IL-2 is sufficient for direct activation of peripheral blood lymphocytes into lymphokine-activated killer cells

1 reference

12 December 2020

Successful immunotherapy of natural killer-resistant established pulmonary melanoma metastases by the intravenous adoptive transfer of syngeneic lymphocytes activated in vitro by interleukin 2

1 reference

12 December 2020

Phase I evaluation of recombinant interleukin-2 in patients with advanced malignant disease

1 reference

12 December 2020

Interleukin 2 induces antigen-reactive T cell lines to secrete BCGF-I.

1 reference

12 December 2020

Production and characterization of monoclonal antibodies to human interleukin 2: strategy and tactics

1 reference

12 December 2020

Selective in Vitro Growth of T Lymphocytes from Normal Human Bone Marrows

1 reference

12 December 2020

In vivo interleukin 2 administration augments the generation of alloreactive cytolytic T lymphocytes and resident natural killer cells

1 reference

12 December 2020

Antibodies to interleukin 2. Effects on immune responses in vitro and in vivo

1 reference

12 December 2020

Identifiers

DOI

10.1007/BF00915254

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:3491089%20AND%20SRC:MED&resulttype=core&format=json

27 September 2019

1 reference